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Abstract
Epithelial-to-mesenchymal transition (EMT) is associated with metastasis formation as well as with generation and
maintenance of cancer stem cells. In this way, EMT contributes to tumor invasion, heterogeneity and
chemoresistance. Morphological and functional changes involved in these processes require robust reprogramming
of gene expression, which is only partially accomplished at the transcriptional level. Alternative splicing is another
essential layer of gene expression regulation that expands the cell proteome. This step in post-transcriptional
regulation of gene expression tightly controls cell identity between epithelial and mesenchymal states and during
stem cell differentiation. Importantly, dysregulation of splicing factor function and cancer-specific splicing isoform
expression frequently occurs in human tumors, suggesting the importance of alternative splicing regulation for
cancer biology.
In this review, we briefly discuss the role of EMT programs in development, stem cell differentiation and cancer
progression. Next, we focus on selected examples of key factors involved in EMT and stem cell differentiation that
are regulated post-transcriptionally through alternative splicing mechanisms. Lastly, we describe relevant oncogenic
splice-variants that directly orchestrate cancer stem cell biology and tumor EMT, which may be envisioned as novel
targets for therapeutic intervention.
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Background
Epithelial cells are typically immobile cells, characterized
by an apical-basal polarity with cohesive cell-cell
junctions connecting adjacent cells in a continuous
monolayer [1]. On the contrary, mesenchymal cells
exhibit a motile and invasive phenotype by adopting an
elongated shape with a front-back polarity [2].
Epithelial-to-mesenchymal transition (EMT) is a devel-
opmental program underlying the acquisition of mesen-
chymal properties by epithelial cells [3]. This process is
fundamental during embryogenesis, when regulated
migration of restricted population of cells is required for
organogenesis [4]. In adult mammals, activation of EMT
is mainly exploited in wound healing. However, this
process is also reactivated by cancer cells to invade
adjacent tissues and to disseminate toward distant or-
gans, representing an essential step during progression
of epithelial cancers to more aggressive stages [4]. Fur-
thermore, EMT has also been involved in generation of
cancer stem cells (CSCs) [5], the subpopulation of cells
identified within leukemias and solid tumors as having
self-renewal and expanding capability, thus contributing
to tumor growth, metastasis and resistance to conven-
tional therapies [6].
EMT relies on profound changes in gene expression that
require multiple layers of regulation, from transcription, to
post-transcriptional RNA processing, to translational and
post-translational modifications. Although transcriptional
regulation by EMT-inducing transcription factors (EMT-
TFs), like members of the ZEB, SNAIL and TWIST families,
is generally considered the master step in this process,
mounting evidence indicates that post-transcriptional events
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strongly contribute to the fine-tuning of EMT [7]. Notably,
post-transcriptional mechanisms of gene expression regula-
tion have recently emerged as important tools exploited by
cancer cells to acquire unique features that confer advan-
tages over surrounding cells and sustain tumor malignancy
[8]. In this regard, splicing of precursor messenger RNAs
(pre-mRNAs) appears particularly suited to fine-tune regula-
tion of gene expression because of its extreme flexibility.
It is clear that alternative splicing (AS) of pre-mRNAs
plays an essential role in generating proteome diversity
in cancer cells, through the production of splice-variants
involved in key oncogenic pathways and resistance to
chemotherapeutic drugs [9–11]. The advent of next
generation sequencing and the development of highly
specific bioinformatics tools have offered the possibility
to study AS regulation with increasing detail. Through
these approaches, a number of cancer-specific AS iso-
forms have been identified [12], paving the ground for
their application in cancer diagnosis and as targets for
selective anti-cancer treatments.
AS regulation modulates several molecular and mor-
phological processes involved in EMT [13, 14]. Since AS
is a versatile and powerful mechanism to both establish
and maintain fundamental properties of different cell
and tissue types [15, 16], it is not surprising that it con-
tributes to promote the plasticity required for the EMT
process and for establishing the stem-like properties that
typify the more aggressive nature of neoplastic cells.
In this review, we offer a brief overview of EMT
programs in development, stem cell biology and cancer
progression. Subsequently, we assess the contribution of
AS in EMT, describing interesting examples of both spli-
cing factors and target genes, and presenting AS profiles
that contribute to the dynamic transitional states between
the epithelial and mesenchymal phenotypes in cancer. We
also focus on the impact of AS regulation in cellular fea-
tures that are directly related to the oncogenic potential of
CSCs and provide examples of AS variants involved in ac-
quisition and maintenance of stem cell-like features.
Main text
Epithelial-mesenchymal transition: a flexible tool for cell
plasticity during embryogenesis
EMT was first characterized during embryonic develop-
ment when a restricted population of epithelial cells
differentiate into motile mesenchymal cells in order to
form new tissues at specific sites, leading to the three-
dimensional organization of developing organs [3, 4].
Differentiation of three embryonic layers during
gastrulation of avian and mammalian embryos is the
proto-typical example of a developmental program rely-
ing on EMT. Epiblastic cells of the primitive streak
undergo EMT to move internally and generate the two
inner layers of mesoderm and endoderm, while
differentiation of the remaining epiblast generates the
ectoderm [17]. EMT also promotes migration of neural
crest cells from the epithelium near the dorsal midline of
the neural tube towards prescribed embryonic regions
where they differentiate to give rise to ganglia of the per-
ipheral nervous system and other neural-derived cell types
[18]. Interestingly, once their final target destination is
reached neural crest cells re-aggregate through a reversible
process of mesenchymal-to-epithelial transition (MET),
which interrupts cell migration inducing these cells to form
novel epithelial tissues [17, 19]. Notably, gastrulation and
neural crest migration represent just two of the many exam-
ples of EMT/MET processes occurring during embryogen-
esis, since several rounds of reversible EMT and MET are
necessary for proper embryo development [20].
Signals from multiple cues orchestrate the proper exe-
cution of EMT/MET cycles during embryogenesis. An ex-
ample of signaling molecule involved in these programs is
provided by WNT, whose signaling pathway promotes
EMT and ingression of epiblastic cells from the primitive
streak during gastrulation [21]. Furthermore, WNT acts
synergically with other regulatory molecules, such as
BMP4, for the induction of EMT in the migratory neural
crest cells during their delamination from the neural tube
[22]. These signal transduction pathways ultimately induce
the expression of EMT-TFs [7]. Indeed, both gastrulation
and neural crest cell migration require increased
expression of SNAIL1 and SNAIL2 (also known as SLUG)
[23, 24], which mediate repression of the epithelial adhe-
sion protein E-cadherin, leading to the disruption of adhe-
rens junctions (AJ) and acquisition of a mesenchymal
migratory morphology. Downregulation of E-cadherin is
not sufficient to induce EMT phenotypic changes, and
regulation of other adhesion molecules is often required.
For example, repression of both E-cadherin and CAD6b
coupled with upregulation of less adhesive type II cadher-
ins, such as cadherin 7 and 11, is required during neural
crest cell migration [25, 26]. Likewise, another EMT-TF,
ZEB1, regulates the E- to N-cadherin switch occurring dur-
ing the transition from the pre-migratory to the migratory
state of the neural crest cells [27], an event necessary for ac-
tivation of directional migration [28]. Another key step in
EMT is the digestion of the extracellular matrix (ECM) of
the basal membrane. This process allows the complete de-
tachment of the cells from the original epithelial layer and
their migration towards the novel site of destination. Deg-
radation of the ECM is mainly mediated by membrane-
bound and/or secreted forms of matrix metalloproteases
(MMPs) [29], such as the MMP-2, which also contribute to
EMT-driven events during embryogenesis [30].
Molecular processes involved in EMT
Epithelial integrity is ensured by specialized cell-cell
junctions organized through the assembly of cell surface
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protein complexes: adherens junctions (AJ), tight
junctions (TJ) and desmosomes (DS) [31]. TJ are mainly
responsible for the sealing of the epithelial layer and ac-
quisition of apico-basal polarity [32]. Transmembrane
proteins, such as MARVEL-domain proteins, occludins,
claudins and junctional adhesion molecules (JAMs)
mediate cell-cell adhesion, whereas cytosolic proteins
(mainly zona occludens family members, ZO1/2/3)
stabilize the junction by binding cytoskeleton compo-
nents and providing the docking sites for polarity
proteins (PAR3, PAR6, PALS1 and PATJ), signaling com-
ponents (aPKC, CDC42, RAC and RHOA) and their
regulators (RHOGEFs and RHOGAPs) [33].
AJ, similarly to DS, display cadherin clusters as core
components [34]. Cadherins are transmembrane pro-
teins that allow cell-cell adhesion among adjacent cells
[35]. Both TJ and AJ are able to interact with the acto-
myosin machinery and this association plays critical
functions for cytoskeleton organization and cell-shape
remodelling [36]. Mechanistically, the link between the
junction and actin or microtubule filaments is provided
by catenins (β-catenin, p120 and α-catenin) [37].
Cadherin-catenin clusters facilitate the recruitment of
cytoskeletal regulators and polarity proteins to the junc-
tional complex [34, 38].
The prevailing models for EMT regulation propose
that a sequential series of events are required for an
epithelial cell to acquire mesenchymal features [7]
(Fig. 1a, b). During the first step, TJ are disassembled by
complete abrogation of occluding and claudin expression
[39]. Together with the loss of the transmembrane back-
bone of the junction, the cytoplasmatic components
(ZO1/2/3) diffuse away from cell-cell contacts [40]. In
addition, loss of E-cadherin is another fundamental
event in EMT [41]. Specifically, E-cadherin is degraded
by proteolytic cleavage or through endocytosis from the
plasma membrane [42, 43], whereas its expression is
repressed (directly or indirectly) by EMT-TFs [44]. As
result of E-cadherin disappearance from the cell mem-
brane, catenins are free to move in the nucleus where
they act as transcriptional regulators of specific mesen-
chymal genes [45].
Disappearance of apical-basal polarity is another
strictly coordinated event in EMT, which involves both
transcriptional repression [46] and re-localization of key
cytoskeletal components to the leading edge of the cell.
For instance, regulation of Par (PAR3/PAR6/aPKC) and
Scribble (Scribble/LGL/DLG) complexes, which specify
apical membrane identity, as well as of the Crumbs
(PALS1/PATJ/Crumbs) complex, which specifies basal
membrane identity, promotes a shift toward a front-rear
polarity [47]. Simultaneously, lamellipodia, filopodia and
invadopodia are formed by actin cytoskeleton remodel-
ing mediated by the CDC42 and RAC signaling
pathways [48]. Globally, these changes shift cell morph-
ology toward a motile and invasive phenotype. Finally,
expression of MMPs [29], which degrade the ECM, to-
gether with the appearance of mesenchymal markers (N-
cadherin, Vimentin, Fibronectin, α5-Integrin) complete
the transition to a motile cell that is able to colonize dis-
tant tissues [45] (Fig. 1a, b).
The acquisition of mesenchymal properties during
EMT occurs progressively along an axis, wherein fully
epithelial and mesenchymal cells represent the extreme
edges [7]. This plastic and dynamic process comprises
several intermediate states, including hybrid phenotypes
in which cells concomitantly express epithelial and mes-
enchymal features [1, 49]. Importantly, cells carrying
such hybrid epithelial/mesenchymal phenotype (referred
as hybrid E/M) not only exert fundamental roles in em-
bryogenesis, but also during cancer progression [50, 51].
Role of EMT in cancer
During malignant progression of epithelial cancers,
tumor cells acquire an invasive and motile phenotype in
order to invade adjacent tissues and disseminate toward
distant organs. This metastasis formation process is re-
sponsible for approximately 90% of cancer mortality
[52]. Notably, metastasis is a highly inefficient process.
Indeed, it has been estimated that, from 10,000 tumor
cells that enter the circulation, only one is able to de-
velop a macroscopic metastasis [53]. Since tumor epithe-
lial cells have cohesive cell-cell junctions that inhibit
their movements, the transition toward a mesenchymal
phenotype through activation of EMT has been pro-
posed as a key step for tumor dissemination and cancer
progression [3]. Although it was initially believed to
occur in advance stages of cancer progression, supported
by the positive correlation between tumor size and
metastatic potential [54], it is now recognized that
tumor dissemination and micrometastases can be found
in early stages of the disease [55]. Accordingly, epithelial
cells undergoing EMT have been found in pre-neoplastic
lesions of pancreatic tissues [56]. As in the course of em-
bryonic development, tumor EMT is a reversible
process, and regain of epithelial features through MET
can also occur at the final metastatic site [57].
Various cues in the tumor microenvironment are
implicated in establishing an intricate network of inter-
actions that activate the EMT/MET programs [58]. Can-
cer cells are associated with a large array of stromal
cells, including fibroblasts, myoblasts, macrophages and
lymphocytes, but also with endothelial cells and peri-
cytes recruited to the tumor vasculature [59]. Paracrine
and juxtacrine signals in such microenvironment include
growth factors and cytokines [60]. In addition, oxidative
stress, hypoxia and morphogenic (NOTCH and WNT)
signaling pathways increase expression of EMT-TFs. The




Fig. 1 (See legend on next page.)
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combined action of these signals, together with the na-
ture of the ECM components, induces cancer cells to
adopt molecular and morphological features of either
epithelial or mesenchymal identity [61]. EMT in cancer
progression follows the same pattern described for physio-
logical EMT programs, with disruption of cell-cell adhe-
sion, loss of polarity and cytoskeleton reorganization,
release of mesenchymal-specific MMPs (MMP-1, MMP-2,
MMP-9, MMP-12 and MMP-13) and degradation of the
ECM that allows invasion of the original tissue and
dissemination [62–64]. Notably, high levels of MMPs in
the tumor microenvironment affect both stromal and can-
cer cells. Stromal cells are induced to produce additional
MMPs (MMP-7 and MMP-14), thus increasing the deg-
radation of the ECM and promoting tumor invasion [65].
Moreover, MMPs can mediate the proteolytic cleavage of
E-cadherin, generating extra-cellular E-cadherin frag-
ments that increase motility [66]. Importantly, expression
of different types of MMPs is associated with worse prog-
nosis in several cancers, including ovarian [67], breast
[68], gastric [69] and colorectal cancers [70].
EMT has also been linked to other aspects of cancer
biology such as inhibition of cellular senescence [71] and
chemoresistance [72, 73]. An interesting example is pro-
vided by ZEB1/2. These EMT-TFs are induced by TGF-β
and repress the cyclin kinase inhibitors p15INK4B,
p16INK4A and p21, thus abolishing EGFR-dependent sen-
escence in esophageal squamous cell carcinoma [74].
Similarly, TWIST cooperates with Ras signaling to pre-
vent oncogene-induced cellular senescence through ab-
rogation of p53- and Rb-dependent pathways [75].
Finally, reduced susceptibility to apoptosis during EMT
is conferred by the action of EMT-TFs on survival path-
ways, mainly MEK/ERK and PI3K/AKT [76], and pro-
apoptotic and anti-apoptotic genes, such as the Bcl2
family members [77].
Activation of EMT has been associated with chemore-
sistance in different tumor types. Enrichment of cells ex-
pressing mesenchymal markers has been detected in
breast, colorectal and non-small lung cancers upon chemo-
therapeutic treatments [78–80]. In line with these observa-
tions, inhibition of EMT-TFs and post-transcriptional
regulators of EMT was found to abrogate EMT-induced
chemoresistance in breast and pancreatic cancer models
[72, 73]. Chemoresistance might result from the combined
activation of the many cellular processes involved in EMT
and may be related to acquisition of stem-like features by
cancer cells. High expression of the EMT-TFs ZEB1 [81],
SNAIL1 and SNAIL2 [82] in cancer cells triggers the
expression of stemness factors SOX2 [81], BMI1 and OCT4
[6, 81, 82]. Notably, mesenchymal and stemness traits are
known to characterize the CSC subpopulation within the tu-
moral mass, which is responsible for tumor metastasis and
resistance to conventional therapy [6]. Thus, EMT might re-
vert the phenotype of terminally differentiated epithelial cells
to a more plastic, mesenchymal phenotype that mirrors
some properties of pluripotent embryonic cells during
organogenesis.
EMT has been shown to be a transient process occur-
ring only in a subset of cells at the invasive front of the
primary carcinoma, usually associated with stromal com-
ponents [83]. Nevertheless, hybrid E/M cells have been
found in different tumors, including breast, ovarian and
lung cancers [84–86] and in some tumor mouse models
[56, 87]. Accordingly, circulating tumor cells (CTCs)
with a fully mesenchymal state display lower metastatic
potential compared to hybrid E/M cells that underwent
a partial EMT [88]. A more heterogeneous expression of
mesenchymal and epithelial markers is detected in CTC
clusters, which are aggregates of 2-50 tumor cells held
together through intercellular adhesions and recruitment
of platelets [88]. CTC clusters are also characterized by
a high metastatic potential taking advantage of both
mesenchymal properties, which sustain cell motility and
invasion [51], and epithelial features involved in extrava-
sation and colonization propensity [89]. Notably, it was
recently reported that also breast CSCs showing an hy-
brid E/M state, characterized as CD24− CD44+ ALDH+,
(See figure on previous page.)
Fig. 1 Significant alternative splicing changes occurring during EMT. a Key transcription factors upregulated during EMT; gradient color represents
their expression increase from epithelial to mesenchymal phenotype. b Schematic representation of EMT progression. From left to right: (i)
polarized epithelial cell with strong cell-cell junctions. Par complex and actin filaments localize to the junctions; (ii) epithelial cell with residual
junctions starts to re-organize its cytoskeleton and change its morphology. E-cadherin disappears from cell membrane (small yellow square). The
Par complex is disassembled and PAR6/aPKC move to the apical cell surface; (iii) the epithelial cell loses its epithelial features and begins to
acquire an elongated and spindle-like morphology, while PAR6/aPKC, with other polarity complexes (not shown), allow the establishment of a
front-rear polarity. Metalloproteases are secreted in order to degrade the ECM; (iv) a motile mesenchymal cell is able to invade the surrounding
tissues. c Expression gradients of key splicing factors regulated during EMT. d Center. AS of genes involved in different EMT programs, including
migration and invasion (FGFR2, RON and CD44), polarity and cytoskeleton organization (NUMB, RAC and p120) and transcription regulation (TCFL2).
Alternative exons are represented in red, mutually exclusive exon in blue. Left. Scheme of epithelial-specific AS variants. Alternative exons and the
encoded amino acids are indicated in red. Right. Mesenchymal-specific isoforms are also shown. Differences in functional properties of epithelial versus
mesenchymal isoforms are highlighted: FGFR2 exons IIIb and IIIc confer different ligand binding specificity; ΔRON and Rac1b are constitutively active
cytoplasmic isoforms; inclusion of exon 6 in NUMB allows it to interact with Par complex and E-cadherin; p120 isoforms 1-2 localize to AJ, whereas
p120 isofoms 3-4 localize with the activate RAC and repress RHOA signaling thus promoting re-organization of the actin cytoskeleton; skipping of exon
4 in TCFL2 generates the more active transcriptional factor TCFL2-Δ4
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displayed the highest invasive ability [90]. These obser-
vations strongly suggest that maintenance of a transient
epithelial-mesenchymal phenotype reflects an increased
cellular plasticity, which allows acquisition and preserva-
tion of stemness traits by cancer cells. This hypothesis is
also supported by several recent studies showing that, in
addition to EMT, the MET pathway can also induce
stem-like properties and increase metastatic potential in
cancer cells. For instance, downregulation of EMT-TFs
in prostate and bladder cancer cells was reported to pro-
mote expression of stemness factors and to enhance
their growth as spheroids [91], the typical pattern of
stem cell growth [92]. Similarly, silencing of PRRX1, a
transcription factor that induces EMT, promotes the ac-
quisition of stem cell properties by breast cancer cells,
enhancing their self-renewal ability and growth in mam-
mospheres [93].
Mechanisms of regulation of EMT: the emerging role of
alternative splicing
EMT requires a robust reprogramming of gene expres-
sion [3]. Several EMT-TFs are activated early during
EMT to either repress epithelial-specific genes or induce
specific mesenchymal features. Epithelial-specific genes,
such as E-cadherin, claudins and occludins, are
repressed by SNAIL proteins (SNAIL1 and SNAIL2)
[41, 94]. SNAIL1/2 bind to epithelial-specific pro-
moters, recruit several epigenetic regulators such as
PRC2 [95], HDAC1/2 [96], LSD1 [97], G9a [98] and
SUV39H1 [99], and promote chromatin condensation
[100]. Similarly, bHLH transcription factors (TWIST1
and TWIST2) and ZEB proteins (ZEB1 and ZEB2) are
able to both repress epithelial genes and stimulate ex-
pression of mesenchymal-specific genes, such as N-
cadherin, fibronectin and matrix metalloproteases
[101–103].
However, the proteomes of mesenchymal compared to
epithelial cells show significant differences [104] only
partially explainable by functions of EMT-TFs. Mounting
evidence suggests that post-transcriptional events, and
in particular AS, significantly contribute to this diversity.
Splicing occurs during transcription, and in some in-
stances post-transcriptionally, when intronic regions are
removed by direct interactions of the splicing machinery
(the spliceosome) with short, poorly conserved, cis-act-
ing sequence elements at exon–intron boundaries
(donor or 5′ and acceptor or 3′ splice sites). This poor
level of conservation allows high flexibility in splice site
recognition, with frequent competition between sites
showing variable strength [105, 106]. By using different
combinations of donor and acceptor sites, more than
90% of human genes are able to generate different
mRNAs through AS of selected exons and introns
(Fig. 2a), thus yielding an estimated number of at least
100,000 different proteins [107]. Regulation of AS is
modulated by the action of cis-acting elements (non-
splice site RNA sequence elements) and trans-acting fac-
tors on the pre-mRNA. Cis-acting elements promote
(splicing enhancers) or inhibit (splicing silencers) the
usage (or definition) of variable exons by providing bind-
ing sites for trans-acting splicing regulators. Cis-ele-
ments can be found alone or clustered in introns (ISE/
ISS, intronic splicing enhancer/silencer) as well as inside
exons (ESE/ESS, exonic splicing enhancer/seilencer)
(Fig. 2b) [105]. Serine-arginine (SR) factors and hetero-
geneous ribonucleoproteins (hnRNPs) are the two major
classes of ubiquitously expressed trans-acting splicing
factors [105]. SR proteins are highly conserved splicing
regulators characterized by the presence of a C-terminus
serine rich domain (the RS domain) implicated in
protein-protein interactions [108] (Fig. 2c). By binding
to splicing enhancers, typically purine rich motifs [109]
through their RNA-recognition motifs (RRM), SR pro-
teins usually promote exon recognition stabilizing spli-
ceosomal components at exon–intron boundaries or
antagonizing splicing repressor (Fig. 2b). However, SR
proteins are also able to stimulate exon skipping
suggesting that their activity is influenced by a complex
network of interactions with the others RNA binding
proteins (RBPs) expressed in specific cell types and/or
development stages [110, 111]. Similar to SR proteins,
hnRNPs have a modular structure with RNA-binding
domains flanked by auxiliary domains with different
functions and properties (Fig. 2c). Generally, hnRNPs
bind to splicing silencers preventing the association of
SR proteins or spliceosome components to alternative
exons [112], thus leading to exon skipping (Fig. 2b).
While SR proteins and hnRNPs are widely expressed
across different tissues and cell types, other splicing fac-
tors display a cell-type-specific pattern of expression. To
date, the best characterized mammalian tissue-specific
AS regulators are NOVA1/2, PTBP2 (also known as
nPTB or brPTB), SRRM4 (nSR100) and members of the
RBFOX, MBNL, CELF, TIA, ESRP and STAR families
(Fig. 2c). For some of these factors, the mode of action
during the AS reaction is very peculiar since it depends
on the position of their binding sites on pre-mRNA tar-
gets. For instance, NOVA1/2 proteins are able to promote
exon inclusion when they bind to cis-acting elements
(YCAYclusters) located in exons or near the 3′ splice site of
the intron, while they promote exon skipping if their binding
sites are located near the 5′ splice site [113]. The tissue-
specific expression pattern of these splicing factors help es-
tablish the appropriate spatio-temporal generation of splice
variants in many cellular and developmental processes [114,
115]. Since some excellent reviews have recently illustrated
the general mechanisms of AS regulation, the reader is re-
ferred to them for additional insight [106, 116].
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Transcription and AS coordinately control different
subsets of genes to generate the molecular and cellular
complexity of cell and tissue types [15, 16, 106, 117].
Thus, it is not unexpected that AS also contributes to
the dynamic (molecular and morphological) cellular con-
version during EMT [118]. In line with this notion, ex-
pression of several splicing factors has been reported to be
modulated during EMT [119]. Since each of them is able
to regulate hundreds of pre-mRNA targets, it is likely that
perturbation of their expression levels can simultaneously
affect different aspects of EMT progression [7].
The ESRP splicing factors: key regulators of epithelial
identity
A salient example of how EMT can be modulated by ex-
pression of specific splicing factors is provided by ESRP1
and ESRP2, two epithelial-restricted splicing regulators
[120–122]. ESRP gain- and loss-of-function cells and
genome-wide based approaches were used to
characterize the ESRP-dependent epithelial splicing sig-
nature and its contribution to EMT [122]. These high-
throughput approaches uncovered an important role of the
ESRP-mediated RNA network in affecting exons of genes
involved in RNA splicing, vesicle-mediated transport system,
cell polarity, cell junction organization, motility and migra-
tion, regulation of small GTPase-mediated signal transduc-
tion and actin cytoskeleton [14, 121–123]. In addition, this
analysis decoded the RNA map by which ESRP1/2 regulate
AS. Indeed, similar to NOVA1/2 and RBFOX2 [113, 124],
ESRP proteins display a positional effect and promote or re-
press exon inclusion depending on the locations of their
binding sites (UGG-rich motifs) in RNA targets [14].
One of the best characterized ESRP targets is the
Fibroblast growth factor receptor 2 (FGFR2) pre-mRNA.
ESRPs control mutually-exclusive regulation of two




Fig. 2 Alternative Splicing regulation. a Scheme of the different AS modalities: (i) cassette exons; (ii) mutually exclusive exons; (iii) intron retention;
(iv) alternative 5′ splice sites; (v) alternative 3′ splice sites; (vi) inclusion of a poison exon containing a premature stop-codon (yellow) leading to
mRNA degradation through NMD. Precursor transcripts and final spliced products are shown. b AS regulation by combined action of trans- and
cis-acting elements. Intronic and exonic splicing enhancers (ISE and ESE) promote the inclusion (+) of the AS exon (red) by providing the binding
sites for activators (orange circles), whereas intronic and exonic splicing silencers (ISS and ESS) are bound by repressors (yellow circles) and promote
exon skipping (-). Generally, ESE-bound SR factors stimulate the assembly of the splicesome on the variant exon or counteract the inhibitory
activity of hnRNPs bound to ESS elements. On the contrary, hnRNPs interfere with the assembly of spliceosome to the variant exon leading to
exon skipping. In addition, hnRNPs by binding ISSs located in the introns flanking a variant exon cause its looping out and skipping, whereas
when bound to ESSs they may polymerize along the exon and displace the ESE-bound SR proteins (not shown). c Some members of the SR and
hnRNP families mentioned in the text are shown with their characteristic domains. SR proteins have a modular structure with one or two RNA recogni-
tion motifs (RRM) in the N-terminus able to interact with the pre-mRNA, whereas at C-terminus all members of this family present a domain of variable
length rich in serine-arginine dipeptides (RS domain) involved in protein-protein interactions with spliceosomal components. HnRNPs possess one or
more RNA-binding domains associated with different “auxiliary” domains that are diverse in sequence and involved in sub-cellular localization or
protein-protein interactions. Tissue-specific AS regulators (RBFOX, MBNL, ESRP and NOVA families) are indicated with their own RNA-binding domains
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critical roles in ligand binding specificity [120]. Splicing
of these exons ensures the appropriate expression of
FGFR2 isoforms and, as a consequence, the correct
FGF/FGFR2 signaling during development. Moreover, al-
tered splicing of exons IIIb and IIIc in FGFR2 pre-
mRNAs was found in primary tumors and metastases
and it was associated with tumor plasticity [125]. ESRPs
repress exon IIIc and increase inclusion of exon IIIb,
leading to production of the epithelial-specific FGFR2-
IIIb isoform. On the contrary, downregulation of ESRP
proteins promote the inclusion of the mesenchymal-
specific exon IIIc and, at the same time, induce molecu-
lar and morphological changes associated with EMT
progression [120, 122]. In order to properly regulate AS
of FGFR2 pre-mRNAs, ESRPs cooperate with other
widely expressed RBPs, including PTBP1 (hnRNP I),
hnRNP A1, M, F and H [126–129]. Thus, the net out-
come of FGFR2 AS in any given cell depends on the spe-
cific repertoire of splicing factors expressed. These
observations suggest that multiple cues could modulate
this EMT-related splicing event by affecting expression
or post-translational modifications of splicing factors in-
volved in this regulation.
An interesting observation is that, in several cases,
ESRP-regulated splice variants exhibit distinct and even
opposing functions during EMT. The p120 pre-mRNA
splicing event that generates two variants (p120 isoforms
3 and 4) is able to promote cell-cell adhesion in epithelial
cells by increasing p120 binding to E-cadherin in AJ [130].
In contrast, the mesenchymal-specific p120 isoform 1 in-
duces cell migration and invasiveness by inhibiting
RHOA-ROCK signaling pathway and stimulating RAC1
activity [131]. Another example of ESRPs target is NUMB
pre-mRNA, which encodes for a factor involved in main-
tenance of cell polarity and cell-cell adhesion by binding
to Par polarity complex and E-cadherin, respectively
[132]. Through its N-terminal phosphotyrosine binding
domain (PTB) domain, NUMB binds a conserved NVYY
motif in the cytoplasmic portion of E-cadherin. Tyrosine
phosphorylation of this motif abolishes NUMB/E-cad-
herin association, allowing NUMB to interact directly with
the Par complex members PAR6 and aPKC [133]. Inter-
estingly, 11 amino acid residues of the PTB domain are
encoded by an epithelial-specific exon whose inclusion is
controlled by ESRP proteins [122]. Skipping of this exon
has been proposed to affect NUMB cellular membrane
localization as well as its interaction with E-cadherin,
resulting in loss of cell-cell adhesion [122].
ESRPs also regulate cell polarity through AS regulation
of SCRIB transcripts [121]. SCRIB is a scaffolding pro-
tein required for epithelial cell identity and prevents
EMT progression by blocking loss of E-cadherin and
ZO1 from AJ [134]. In contrast with these roles, SCRIB
knockdown has been associated with impaired cell
migration and downregulation of mesenchymal markers
[135]. The apparent antithetical functions of SCRIB in
cell migration and EMT could be partially explained by
the ESRP-dependent splicing of SCRIB pre-mRNAs,
where SCRIB epithelial-isoform is required for AJ stabil-
ity, whereas the mesenchymal-specific variant is involved
in cell motility [136]. Splicing changes of ESRP target
exons also affect actin cytoskeleton organization and its reg-
ulators. The ENAH gene generates an epithelial-specific
splice variant, derived from inclusion of a small exon (exon
11A) encoding 21 amino acids in the C-terminal Eva/Vasp
homology (EVH2) domain [137]. Downregulation of this
variant was linked to tumor invasiveness in vivo [138],
whereas a mesenchymal specific isoform lacking exon
6 (ENAH-Δ6) was associated with invasiveness in
mesenchymal-like breast tumors [139]. In addition, ENAH
interacts with ABI1, another ESRP target gene involved in
actin cytoskeleton remodelling and cell-cell adhesion [140].
Remarkably, ESRP-mediated AS of ABI1 pre-mRNA influ-
ences the sequence of the proline region domain important
to mediate ABI1 association with several partners, including
ENAH [140].
Other ESRP targets include cell membrane proteins
such as integrins and receptors (KITLG, MPZL1, ITGA6,
CD46, CD44) that are able to sense environmental signals,
but also components of signaling pathways involved in
EMT (MAP3K7, SOS1 and FYN) [122]. Moreover, ESRPs
could act indirectly on expression levels of epithelial tran-
scripts, as they stimulate inclusion of exon 4 of the
TCF7L2 transcription factor, thus promoting an isoform
with reduced ability to activate β-catenin-target genes in
epithelial cells [141]. Additionally, ESRP-mediated AS of
ITGA6, CD46 and MAP3K7 variant exons causes intro-
duction of premature stop-codons able to induce mRNA
degradation through non-sense mediated decay (NMD)
[122], a process known as alternative splicing activated
NMD (AS-NMD) [142].
Many ESRP-regulated pre-mRNA targets encode pro-
teins that interact with each other (Fig. 1c, d). This ob-
servation suggests that ESRPs control a network of
epithelial regulators and that AS plays an important role
in affecting physical interactions between these factors
during activation of EMT programs. Hence, the pheno-
typic changes reported upon ESRPs knockdown are
likely the integrated effects of several AS changes that
may act in a coordinated manner. Considering the es-
sential role of ESRPs in coordinating epithelial cell-type-
specific AS programs, several groups have investigated
how their expression level are regulated. Collectively, it
was proposed that downregulation of ESRPs can be in-
duced by transforming growth factor (TGF)-β-induced
EMT [143, 144], epigenetic mechanisms [145] and gene
mutations [146]. Notably, ESRP1 is among the most
downregulated genes in different EMT experimental
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models [119, 144, 147–149], indicating that its presence
may represent an obstacle to acquisition of mesenchy-
mal features. In line with this hypothesis, the EMT-TF
ZEB1, which is upregulated in several human cancers
[150, 151], directly inhibits ESRP1 expression, thus caus-
ing AS changes in the CD44 gene [120]. CD44 encodes a
cell surface glycoprotein that binds different components
of the extra-cellular matrix [152]. Repression of ESRP1
by ZEB1 promotes expression of a mesenchymal CD44
splice variant (CD44s) [153]. Importantly, switch from
epithelial isoforms (CD44v) to CD44s was proposed to
play a role in EMT [154]. Notably, ZEB1 downregulation
was associated to a more invasive phenotype in lung
cancer [153], suggesting that ZEB1-induced EMT and
ESRP1-mediated splicing of CD44 could contribute to
initial transitions of the metastatic progression. On the
other hand, increased expression of ESRPs is linked to
better survival in colorectal cancer [155], whereas ESRP1
upregulation is proposed as a favorable prognostic factor
in pancreatic ductal adenocarcinoma [156]. In addition,
during squamous cell carcinogenesis expression levels of
ESRPs seem to be very dynamic with their downregula-
tion observed at the invasive front of the tumor and re-
expression in lymph node metastases [157]. All these
finding suggest that changes in expression levels of ESRP
proteins and, as a consequence, the dynamic regulation
of AS of their targets, could contribute to EMT plasticity
during malignant transformation.
Other splicing factors involved in EMT/MET processes
In addition to ESRPs, other splicing factors contribute to
EMT-associated AS changes [14] (Fig. 1c, d). RBM47, an
RBP involved in pre-mRNA splicing, mRNA stability
and RNA editing [158, 159], is downregulated during
EMT. Notably, RBM47 regulates many splicing cassette
exons in the same direction of ESRPs, suggesting a
functional combinatorial co-regulation between these
splicing factors to promote epithelial splicing patterns
[14]. However, some AS events seem to be regulated
with opposing effects by ESRPs and RBM47, thus indi-
cating a more complicated pattern of interactions
between these proteins during EMT.
If ESRP proteins are fundamental to establish an
epithelial-specific splicing program, RBFOX2 and MBNL1
are important contributors of the mesenchymal splicing
signatures [160] (Fig. 1c, d). In particular, expression of
RBFOX2 is induced during EMT [119], whereas Rbfox2
transcripts were found more abundant in normal mesen-
chymal tissues compared to epithelial ones [161]. Notably,
RBFOX2 downregulation causes a partial reversion in cell
morphology and motility towards an epithelial phenotype
[119, 149] and these defects correlate with AS changes in
an organizer of actin cytoskeleton (Cortactin), a polarity
protein (PAR3) and a component of the vesicle-mediated
transport system (Dynamin 2) [149]. Interestingly, some
of the RBFOX2 targets (NUMB and MAP3K7), for which
RBFOX2 promotes the production of the mesenchymal-
specific isoform, are also regulated by ESRPs in epithelial
cells in order to generate their epithelial-specific protein
[122]. However, in other cases RBFOX2 was also found to
promote epithelial splicing [149]. This scenario is further
complicated by the recent observation that RBFOX2 co-
operates with Quaking (QKI), an RBP of the STAR (signal
transduction and activation of RNA) family [162], in the
splicing regulation of common pre-mRNA targets [14].
MNBL1 is another RBP that regulates mesenchymal-
specific AS profiles [119]. For instance, MNBL1 cooper-
ates with RBFOX2 in generating mesenchymal isoforms
of ADD3 and LRRFIP2 genes, whereas a competition
between MNBL1 and PTBP1 is present in the case of
PLOD2 and INF2 pre-mRNAs [161]. Interestingly,
MNBL1 is also implicated in other aspects of RNA me-
tabolism [163, 164]. It has been recently reported that
MBNL1 promotes the mRNA stability of two genes in-
volved in metastasis suppression (DBNL and TACC1)
and this effect was linked to breast cancer metastatic
colonization, a cancer type where MBNL1 expression
was associated to metastasis-free survival [165].
Members of the SR family, such as SRSF1 and SRSF3,
are also regulated during EMT and play a role in its pro-
gression [166, 167] (Fig. 1c, d). SRSF1 (historically
known as SF2/ASF) is upregulated in many human tu-
mors and its over-expression increases cell proliferation,
delays apoptosis and is sufficient to transform human
and mouse mammary epithelial cells in vivo and in vitro
[168, 169]. Upregulation of SRSF1 occurs through differ-
ent mechanisms acting at the transcriptional [170], post-
transcriptional [171, 172] and post-translational levels
[168, 173]. Notably, in the past our group has contrib-
uted to demonstrate that SRSF1 expression levels are dy-
namically controlled in epithelial and mesenchymal cells
through AS-NMD of an intron in the 3′UTR of the
SRSF1 gene. In particular, AS-NMD of SRSF1 tran-
scripts, which is altered in colon cancer, is controlled
through the STAR protein SAM68 [171], a RBP linked
to neoplastic transformation and tumor progression
[174, 175]. At post-translational level, SRSF1 activity is
instead regulated through phosphorylation by kinases
that are often upregulated in human cancers [176], such
as SRPK1 [166] and NEK2 [177]. Upon phosphorylation,
SRSF1 localizes to the nucleus [178] where it modulates
AS of several genes involved in motility and invasiveness
[10]. Among SRSF1 pre-mRNA targets, splicing of the
proto-oncogene RON was the first example of an AS
event linked to EMT activation [110]. RON is a tyrosine
kinase receptor that activates a signaling cascade leading
to cell dissociation, migration and matrix invasion [179].
Interestingly, the constitutively active ΔRON isoform,
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generated through AS of a cassette exon of 147 nucleo-
tides, is able to confer increased motility to the cell
[180] and it is frequently over-expressed during tumor
progression of epithelial cancers [110, 181]. SRSF1 stim-
ulates skipping of exon 11 and promotes the production
of ΔRON, which in turn activates the EMT program
[110]. Importantly, ΔRON production is also promoted
by hnRNP A2/B1, another hnRNP proteins involved in
EMT and altered in several cancers [182, 183], whereas
it is inhibited by hnRNP A1, which in this way activates
the reversal MET program [184]. In parallel, the cancer
associated ΔRON splice variant was analyzed as a poten-
tial target for the development of new anti-cancer thera-
peutic strategies. Bifunctional antisense oligonucleotides
or small-molecule inhibitors of SRSF1 activity showed a
positive effect in correcting ΔRON splicing toward an in-
crease exon 11 inclusion [185]. Notably, in addition to
preventing the production of the ΔRON isoform, inhibi-
tors of SRSF1 activity were also able to affect the inva-
sive phenotype of the cells [185]. Several additional
splicing targets of SRSF1 have now been identified by
RNA-seq in breast cancer cells [186]. Among them,
SRSF1 stimulates the production of the constitutive ac-
tive variant of the Rac1 gene (called Rac1b), which is
generated from the inclusion of a highly conserved cas-
sette exon [187] and is characterized by an increased
Rac GDP/GTP exchange activity [188]. Rac1b, expressed
in several tumors [189], affects the EMT process in dif-
ferent ways: by increasing reactive oxygen species (ROS)
and subsequently inducing the EMT-TF SNAIL [190]; by
upregulating of the mesenchymal marker Vimentin
[190]; or bypassing oncogenic induced senescence in
lung and colorectal cancer [191, 192]. Interestingly,
ESRPs contribute to repression Rac1b expression spli-
cing in epithelial cells emphasizing, once again, the inte-
grated effects of several AS factors to determine the
epithelial or mesenchymal identity.
AS in stem cell differentiation
EMT represents a typical example of cellular plasticity,
which promotes differentiation from one phenotype to an-
other during developmental or pathological programs.
The cell types displaying the highest extent of plasticity in
our body are the stem cells. Thus, it is not surprising that
these cells exploit molecular processes that amplify the
flexibility and plasticity of their genome, like AS. Indeed,
recent evidence has linked AS regulation to stem cell biol-
ogy and some remarkable examples are reported below.
Stem cells are undifferentiated pluripotent cells, which
are distinguished from other cells because of their ability
to asymmetrically divide, to either self-renew themselves
or to generate cells committed to differentiation towards
a specific cellular lineage [193]. AS of specific genes
can modulate the balance between self-renewal and
differentiation in response to developmental or environ-
mental cues, thus influencing the developmental poten-
tial of tissues and organs [194].
In the last decade, several studies based on high-
throughput sequencing have uncovered genome-wide
AS programs regulated during differentiation of pluripo-
tent embryonic stem cells (ESCs) into different cellular
lineages [195–197]. Moreover, widespread splicing varia-
tions have been also observed during differentiation of
multi- and unipotent stem cells, as occurring during
neurogenesis [198], hematopoiesis [199] and myogenesis
[200, 201]. Notably, global changes in AS patterns also
occur during the in vitro derivation of ESCs from the
inner cell mass of blastocysts [202], suggesting that
widespread AS reprogramming are not only required
during the differentiation of stem cells, but also for the
acquisition of their stemness features. This notion is also
supported by high-throughput analyses of transcriptome
changes during the cell reprogramming [203–205].
These analyses revealed that reprogramming of somatic
cells to induced pluripotent stem cells (iPSCs) is accom-
panied by a progressive reversion of their splicing profile
toward one that closely resemble that of pluripotent
ESCs [203]. Intriguingly, orthologous genes display evi-
dence of high conservation in the AS patterns activated
during ESCs differentiation and iPSCs induction [160,
197, 206], further supporting an important evolutionary
role of AS regulation in the biology of stem cells.
Splicing changes occurring during iPSCs induction do
not just reflect the phenotypic transition taking place,
but they play an active role in reprogramming, as dem-
onstrated by the ability of iPSCs specific splice-variants
of the Ccne1 and Grlh1 to enhance acquisition of stem-
ness by somatic cells [204, 207]. Importantly, the splicing
program activated during iPSCs reprogramming is re-
versible, as iPCSs redifferentiation to somatic cells leads
to re-establishment of the original somatic splicing pro-
file [160]. Overall, these observations highlight the piv-
otal role of AS in the flexible and reversible regulation
of gene expression operated by stem cells upon their
switch between self-renewal and differentiation.
One of the major mechanisms by which AS regulates
stem cells biology is the generation of splice-variants of
key factors controlling the balance between pluripotency
and differentiation (Fig. 3). In this regard, an interesting
example is represented by the transcription factor
FOXP1. Pluripotent ESCs and iPSCs exclusively express
a specific FOXP1 splicing isoform (FOXP1-ES), which
includes exon 18b and encodes for a protein isoform
having different DNA binding properties with respect to
the canonical factor expressed in differentiated somatic
cells [197]. Differently from the somatic isoform,
FOXP1-ES activates the expression of pluripotency
genes, such as Oct4 and Nanog, and its expression is
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critical for self-renewal and pluripotency of ESCs, as well
as for efficient iPSC reprogramming [197] (Fig. 3). Like-
wise, pluripotent stem cells preferentially express
MBD2c, an AS variant of the methyl-CpG binding pro-
tein MBD2a that is mainly expressed by differentiated
cells [208]. While both proteins are enriched at the
promoters of Oct4 and Nanog, only MBD2a is able to
interact with repressive chromatin remodelling com-
plexes (Fig. 3). Accordingly, MBD2a overexpression
negatively regulates transcription of core pluripotency
factors in iPSCs, whereas MBD2c enhances somatic cells
reprogramming [208]. Splice variants with different plur-
ipotency capacity have been described also in other key
transcriptional regulators of pluripotency, such as OCT4
[209] and NANOG [210], thus further highlighting the
importance of AS in expanding the coding capability of
transcriptomes in regulating stem cells biology.
AS may also affect proliferation and differentiation of stem
cells by regulating steady-state expression levels of specific
mRNAs. Indeed, recent advances in next-generation sequen-
cing technologies have revealed that pervasive intron reten-
tion coupled to NMD and other nuclear RNA surveillance
mechanisms control developmentally-regulated expression
of selected gene subsets during differentiation of multi- and
uni-potent stem cells, including neurogenic [211] and
hematopoietic [212] lineages. For instance, during early
Fig. 3 Significant alternative splicing changes occurring during stem cell differentiation. Center. Splicing factors and AS of genes involved in
somatic cell reprogramming; gradient color represents splicing factor expression increase/decrease from ESCs or iPSCs to differentiated cells. Left.
Scheme of ESCs or iPSCs-specific AS variants. Alternative exons and the encoded amino acids are indicated in red. Right. Differentiated cells-
specific isoforms are also shown. Differences in functional properties of pluripotent versus differentiated isoforms are highlighted: FOXP1 mutually
exclusive exons confer different DNA binding properties; MBD2 AS variants c and a are both enriched at the promoters of Oct4 and Nanog, but
only MBD2a is able to recruit chromatin remodeling complexes to repress pluripotency factors transcription; PRDM14-ES, ZNF207 A/C and GRHL1-
FL enhance somatic cells reprogramming, whereas their AS isoforms, lacking the alternative exon, counteract reprogramming
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phases of neurogenesis, the splicing factor PTBP1 promotes
intron retention of 3′-terminal introns within genes encod-
ing for presynaptic proteins. Intron retention targets these
transcripts to nuclear degradation and prevents their preco-
cious expression during neuronal development. Then, the
progressive decrease of PTBP1 expression during neuronal
differentiation allows splicing of regulated introns, thus
ensuring the appropriate developmentally controlled expres-
sion of target mRNAs [211]. Consistently with the great im-
pact exerted by AS regulation in the control of the balance
between pluripotency and differentiation of stem cells,
different genome-wide RNA interference (RNAi)
screenings identified several RBPs and RNA process-
ing factors as key regulators of self-renewal properties
of stem cells [203, 213–215]. In particular, search for
critical genes required for the reprogramming of mi-
totic cells in iPSCs identified splicing factors SON
[214] and SRSF11 [215]. Notably, these splicing factors
behave as crucial players with opposite functions in the
acquisition and maintenance of stemness. While SON en-
hances somatic cell reprogramming and positively regulates
maintenance of stemness, SRSF11 acts as a repressor and
negatively regulates the acquisition of the stemness pheno-
type. Both studies also revealed putative splicing targets in-
volved in somatic cells reprogramming. SON regulates
splicing of a critical pluripotency transcriptional regulator
PRDM14, thus promoting a long isoform containing exon 2
that enhances reprogramming [214]. SRSF11 promotes exon
9 skipping in ZNF207, leading to a shorter isoform that
counteracts reprogramming [215] (Fig. 3).
Bioinformatics analyses of potential regulators of the
AS changes observed in stem cells and differentiated
cells revealed additional splicing factors as critical regu-
lators of the balance between self-renewal and differenti-
ation [160, 205, 206]. Search for binding motifs enriched
within AS events regulated between stem and somatic
cells discovered MBNL1 and MBNL2 proteins as pos-
sible major regulators [206]. Accordingly, MBNL1 and
MBNL2 are scarcely expressed in ES cells and actively re-
press stem-specific AS variants in differentiated cells
[206]. In particular, MBNL1 and MBNL2 inhibit FOXP1-
ES splicing [206] and their overexpression impairs iPSCs
induction [160, 206]. Similarly to MBNL1/2, also RBFOX2
negatively regulates production of stem cell-specific splice
variants and its overexpression inhibits somatic cells re-
programming [160] (Fig. 3). On the other hand, ESRP1
enhances reprogramming of somatic cells into pluripotent
cells. Putative binding sites for this protein were found up-
stream of exons undergoing skipping during somatic cells
reprogramming. As an example, ESRP1 promotes splicing
of the longest isoform of Grlh1, which enhances cell
reprogramming [205].
The importance of RBPs and splicing factors for the
regulation of stem cell fate is also supported by knock-
out mouse models. For example, genetic ablation of
Ptpb1 causes embryonic lethality shortly after implant-
ation [216, 217], while depletion of its paralog Ptpb2
impairs the embryonic splicing program required for
neuronal maturation [218]. Establishment and mainten-
ance of the AS programs accompanying stem cell fate
requires the controlled expression of the splicing factors
that regulate these programs. Transcriptome changes
occurring during ES differentiation or iPSCs generation
revealed regulation in the expression of several RNA
processing factors, including RBM47, Zcch4 beside the
previously mentioned MBNL1/2, ESRP1 and RBFOX2
[160, 202, 206]. Notably, key transcription factors regu-
lating pluripotency also control the expression of spli-
cing factors with a role in stem cell biology. For
instance, SRSF2, which enhances self-renewal of ESCs
by promoting MBD2c splicing (Fig. 3) and OCT4 and
NANOG expression, is in turn positively regulated by
OCT4 [208]. The cross-regulation between SRSF2 and
OCT4 suggests the existence of a positive feedback loop
between splicing regulators and transcription factors that
reinforces stemness features. Importantly, this regulatory
loop involves both transcriptional and post-
transcriptional regulatory mechanisms, as OCT4 not
only binds the SRSF2 promoter, but it also negatively
regulates the expression of miRNAs targeting its 3′UTR,
such as miR-301b and miR-130b [208]. Moreover, OCT4
promotes the expression of miR-302 family members
[208, 219], which specifically target the somatic-specific
MBD2a isoform, but not the stem-specific MBD2c vari-
ant [208], thus further reinforcing a stemness positive
feedback-loop. Additional evidence highlighting the ex-
istence of a crosstalk between transcriptional and spli-
cing regulators in stem cell biology arises from a recent
study showing that early epigenetic reprogramming oc-
curring during iPSCs induction is functional to control
the expression of several splicing regulators leading to
activation of an AS program that is crucial for repro-
gramming [220]. The histone acetyltransferase GCN5
functions as an early mediator of the global epigenetic
changes occurring during early phases of iPSCs induc-
tion. GCN5 cooperates with the reprogramming factor
c-MYC in the regulation of its target genes, including
several splicing regulators such as such U2AF1, TRA2B
and SNRP70. Depletion of GCN5/c-MYC impacts on
the AS program activated during the early phases of
somatic cell reprogramming, particularly affecting genes
involved in the regulation of cell adhesion and migration
[220]. Notably, AS itself may also contribute to regulate
the expression of splicing factors controlling stem cells
proliferation and differentiation. For example, RBFOX2,
which promotes ESC differentiation, directly regulates
the steady-state expression levels of several other spli-
cing regulators by AS-NMD mechanisms [124, 221].
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Collectively, AS regulation represents an optimal tool
to maintain stem cell plasticity and redefine develop-
mental fate according to differentiation signals.
Alternative splicing regulation in CSCs
Acquisition of stem-like features in more aggressive can-
cer cells has been frequently correlated to the expression
of oncogenic splice-variants produced as a consequence
of aberrant AS regulation. For instance, widespread
alteration in the splicing programs of leukemia stem
cells (LSCs) compared to normal stem and progenitor
cells were revealed by high-throughput screenings in
both chronic myeloid leukemia (CML) [222] and acute
myeloid leukemia (AML) [223]. Both studies also identi-
fied a global dysregulation in the expression of genes en-
coding for spliceosomal proteins and RNA processing
factors, further suggesting that aberrant AS regulation
may contribute to LSCs generation [222, 223] and that
this may occur independently from oncogenic mutations
in splicing regulatory genes that are frequently observed
in different types of leukemia [223, 224]. Interestingly, it
has been recently suggested that downregulation of the
splicing regulator MBNL3 in LSCs enhances splicing of
the CD44 v3 isoform, which positively regulates their
self-renewal capacity [225]. As previously described,
MBNL3 belong to a family of splicing regulators that
promote ESC differentiation [206]. Thus, aberrant spli-
cing events observed in CSCs may be correlated to re-
activation of embryonic splicing programs [225],
similarly to what described for the activation of the
EMT pathway [226]. This hypothesis is consistent with
the expression of other oncogenic/embryonic AS vari-
ants in cancer cells. For instance, PKM2 is the embryonic
splice-variant of the PKM gene that promotes aerobic gly-
colysis and sustains cancer cells proliferation and metabol-
ism [227]. Interestingly, one of the four transcription
factors necessary for iPSCs induction, c-MYC [228], in-
duces the expression of oncogenic splicing factors (PTBP1
and hnRNP A1/A2) in cancer cells, which in turn promote
PKM2 splicing [229]. Notably, promotion of PKM2 spli-
cing was recently shown to confer chemotherapeutic re-
sistance in pancreatic cancer [230]. Conversely, the tumor
suppressor RBM4 [231] promotes neuronal differentiation
of human mesenchymal stem cells by enhancing PKM1
splicing [232], thus further suggesting that modulation of
the embryonic splicing program might regulate acquisi-
tion and maintenance of stemness features.
Splicing events supporting stemness and proliferation of
CSCs have been described for genes involved in different
cellular functions, such as apoptosis, signal transduction
and cell-adhesion. For example, LSCs were shown to ex-
press high levels of the anti-apopoptic splice variants of
the BCL-2, MCL1, BCLXL, and BFL1 genes [233], as well
as an AS variant of the GSK3-β gene that increases LSCs
self-renewal [234]. High expression levels of the splicing
regulator PTBP1 in brain tumor cells lead to skipping of
exon 6 in the ANXA7 transcripts, generating a shorter iso-
form of this membrane protein, named isoform 2, which
enhances EGFR signaling and promotes cell tumorigen-
icity [235]. A common splicing event in CSCs of different
tumor types is the inclusion of the variable exons of the
CD44 gene. Expression of the CD44v variants is displayed
in both LSCs [225] and CSCs of solid tumors, such as
colon [236] and gastric [237] cancers, with each tumor
type expressing one or more specific variable exons: v3 in
LSCs, v6 in colon cancer and v8-10 in gastric cancers.
Moreover, splicing of the variable exons of v8-10 has been
shown to promote CSC-like features in prostate cancer
cells [238] and to increase the invasive and tumorigenic
potential of bladder cancer cells [239]. Several splicing fac-
tors have been shown to enhance splicing of the CD44
variable exons in cancer, such as SAM68 [240], RBM3
[238] and ESRP1 [120], suggesting that regulation of their
expression or activity may underlie CD44 splicing control
in CSCs. Intriguingly, CD44v splice variants represent a
marker of CSCs even though they are considered epithe-
lial isoforms. Indeed, as aforementioned, the switch from
a CD44v toward a CD44s splicing pattern under the con-
trol of ESRP1 has been correlated with the EMT of both
mammary [154] and bronchial epithelial cells [153]. How-
ever, expression of epithelial markers by stem cells is not
completely surprising, as a MET phase occurs also during
reprogramming of somatic cells into iPSCs [241]. It is thus
conceivable that expression of CD44v in CSCs is func-
tional to the re-establishment of an epithelial phenotype,
which allows engraftment of cancer cells in the site of sec-
ondary lesions during metastasis. Moreover, considering
the high heterogeneity in CD44 isoforms expressed by
CSCs, which has been documented in breast cancer [242],
it is also plausible that regulation of CD44 splicing may
allow CSCs to maintain the hybrid E/M state that has
been correlated with higher stemness and tumorigenicity
[51, 243]. Regulation of CD44 splicing clearly demon-
strates the great impact that this post-transcriptional regu-
latory mechanism exerts on CSCs biology, paving the way
for further studies aimed at identifying new splice variants
and splicing regulators that may represent valuable targets
for new approaches interfering with CSCs phenotypic
plasticity.
Conclusions
Epithelial and mesenchymal cells, as well as pluripotent and
differentiated cells, represent extreme edges of tightly regu-
lated processes: EMT and stem cell differentiation, respect-
ively. In cancers, EMT is linked to metastasis formation as
well as CSC generation and maintenance. Tumor popula-
tions are highly heterogeneous. Indeed, not all cancer cells
are able to undergo EMT at the same time and not all cells
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that have activated an EMT program become competent to
form metastasis. Tumor heterogeneity is further increased
by the existence of epithelial/mesenchymal hybrids in highly
metastatic CTCs and CSCs. Together these findings strongly
suggest the importance of cellular plasticity for the acquisi-
tion of both invasive capabilities and stemness traits.
High-throughput approaches have recently documented
remarkable changes in AS profiles of specific genes dur-
ing activation of EMT programs and CSC generation.
Frequently, such alterations are caused by changes in the
expression levels of trans-acting factors. These analyses
point out that AS provides an additional and extremely
flexible layer of regulation to rapidly control temporal
and spatial expression of protein isoforms, thus shaping
cell- and tissue-identity. Importantly, AS variants orches-
trate several important aspects of the EMT process, in-
cluding cell-cell contacts, polarity and cytoskeleton
organization, and CSC self-renewal and differentiation.
Moreover, the pivotal role of AS regulation in tumor plas-
ticity is underscored by the observation that this mechan-
ism rapidly shifts the expression of protein isoforms with
opposite functions. Finally, the recent optimization of
antisense oligonucleotides-based approaches to selectively
control splicing switches [244–246] suggests that AS vari-
ants specifically expressed during tumor EMT and in
CSCs could represent valuable diagnostic or therapeutic
options for anti-cancer purposes in the near future. How-
ever, although an enormous work in the field has already
been done, the examples that we have discussed likely
represent just the tip of the iceberg, and much more re-
mains to be uncovered in order to draw a more realistic
picture. Thus, future studies are warranted to fully eluci-
date the real contribution of AS regulation to cancer
progression.
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